Evidence map›Paper›PMID 34312609›Full record

ArticleAME case reports2021

Complete response to neoadjuvant pembrolizumab and capecitabine in microsatellite stable, Epstein-Barr virus-positive, locally advanced gastric adenocarcinoma: case report.

Ching Ying Lin, Pareen Mehta, Kevin M Waters, Elena Chang, Andrew Hendifar, Arsen Osipov, Miguel Burch, De-Chen Lin, Alexandra Gangi, May Cho and 1 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in AME case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Ching Ying LinDepartment of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA.
Pareen MehtaDepartment of Imaging, The Angeles Clinic and Research Institute, Los Angeles, CA, USA.
Kevin M WatersDepartment of Pathology, Cedars Sinai Medical Center, Los Angeles, CA, USA.
Elena ChangDepartment of Pathology, Cedars Sinai Medical Center, Los Angeles, CA, USA.
Andrew HendifarDepartment of Hematology/Oncology, Samuel Oschin Cancer Center, Los Angeles, CA, USA.
Arsen OsipovDepartment of Hematology/Oncology, Samuel Oschin Cancer Center, Los Angeles, CA, USA.
Miguel BurchDepartment of General Surgery, Cedars Sinai Medical Center, Los Angeles, CA, USA.
De-Chen LinDepartment of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA.
Alexandra GangiDepartment of Surgical Oncology, Samuel Oschin Cancer Center, Los Angeles, CA, USA.
May ChoDepartment of Medicine, UC Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Jun GongDepartment of Hematology/Oncology, Samuel Oschin Cancer Center, Los Angeles, CA, USA.
Cedars-Sinai Medical Center · USAngeles Clinic and Research Institute · USUniversity of California, Davis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy has been established as a standard in select molecular subgroups of treatment-refractory advanced gastric cancer. However, its role in resectable gastric cancer where perioperative systemic therapy is the standard remains unclear. We present a case of a man who was diagnosed with resectable gastric cancer that was microsatellite stable but programmed death-ligand 1 (PD-L1) and Epstein-Barr Virus (EBV)-positive. Given extenuating circumstances of the SARS-CoV-2 pandemic, preferences to limit exposure to the healthcare setting, and the unique tumor molecular features, neoadjuvant pembrolizumab and capecitabine was pursued after multidisciplinary discussion. He was able to achieve a complete response to this neoadjuvant regimen with no further signs of radiographic or pathologic disease on follow-up. We highlight a dramatic response to this novel approach that represents among the first cases to support a potentially viable neoadjuvant chemoimmunotherapy strategy to resectable gastric cancer. In select patients, perioperative immunotherapy-based therapy may constitute a promising strategy in resectable gastric cancer and warrants further investigation.

Indexed as

case reportEpstein-Barr virusGastric cancerimmunotherapyneoadjuvant therapypembrolizumab

Identifiers

PMID34312609
PMCPMC8256116
OpenAlexW3170233077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.